PET/MR imaging of neoplastic and inflammatory lesions by Catalano, Onofrio Antonio
  
 University of Groningen
PET/MR imaging of neoplastic and inflammatory lesions
Catalano, Onofrio Antonio
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Catalano, O. A. (2018). PET/MR imaging of neoplastic and inflammatory lesions. [Groningen]: University of
Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the







From: An overview of PET/MR, focused on clinical applications. 
Catalano OA, Masch WR, Catana C, Mahmood U, Sahani DV, Gee MS, Menezes 
L, Soricelli A, Salvatore M, Gervais D, Rosen BR. 
Abdom Radiol (NY). 2017;42(2):631-644 
 
From: Nuclear Medicine Imaging in Pediatric Infection or Chronic Inflammatory 
Diseases. 
Signore A, Glaudemans AWJM, Gheysens O, Lauri C, Catalano OA. Semin 
Nucl Med. 2017;47(3):286-303 
 
From MR-PET of the body: Early experience and insights. 
Ramalho M, AlObaidy M, Catalano OA, Guimaraes AR, Salvatore M, Semelka 
RC. 
Eur J Radiol Open. 2014;1:28-39 
 
From: Hybrid imaging in Crohn's disease: from SPECT/CT to PET/MR and new 
image interpretation criteria. 
Catalano O, Maccioni F, Lauri C, Auletta S, Signore A. 




Imaging inflammation and cancer by PET/MR 
 
PET/MR is an innovative hybrid imaging technique that allows acquiring and fusing 
anatomical and functional data from magnetic resonance (MR) with metabolic 
information from positron emission tomography (PET) (1,2). MR and PET may be 
acquired simultaneously (co-acquisition) or sequentially (1,2). In the setting of co-
acquisition, the MR and PET components simultaneously image the same body 
region. This allows for complete spatial and temporal matching of MR and PET data 
(1). 
 Development of PET/MR has recently advanced with innovations such as larger 
bore MR scanners, magnetic field insensitive avalanche photodiodes, and cupper 
shielding (3). 
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Precise quantification of attenuation correction by PET/MR is challenging (3). A 
variety of methods such as Dixon-based tissue decomposition to atlas-based 
attenuation maps, to ultra-short echo time sequences (UTE), have helped but not 
completely resolved this issue (3–5).  
PET/MR is the only hybrid imaging technology capable of co-acquisition of PET with 
morphologic imaging. This ensures temporal and spatial correlation of morphologic 
and functional data with one technique potentially complementing the other. In 
particular, PET quantification may be improved by MR anatomic information, which 
in turn may help in vivo validation of functional MR techniques (6).  Moreover, MR-
driven PET motion correction may reduce blurring and improve PET quantification 
in the case of patient motion, respiration, and bowel peristalsis (7).   
PET/CT is the most accurate imaging technique for the staging of several solid 
organ neoplasms, with accuracy higher than CT or PET alone (8,9).  PET detects 
metabolically active lesions and quantifies the amount of radiotracer uptake, 
expressed as standard uptake value (SUV), which might be helpful in evaluating 
treatment response (10,11). However, PET/CT is limited by the asynchronous 
acquisition of PET and CT, that induces potential miss-match between PET events 
and corresponding anatomic correlates, and by the ntrinsically low soft tissue 
contrast of CT. Moreover, background physiologic radiotracer activity in conjunction 
with the low soft tissue resolution of CT can compromise detection of lesions with a 
low metabolic rate (for example some low-grade lymphomas) (12–19).  
On the contrary, PET and MR data can be acquired simultaneously in PET/MR, with 
an ideal matching of the metabolic data of PET and the morphofunctional 
information of MR.  This optimizes anatomic correlates for PET events and can 
produce unique hybrid biomarkers to potentially investigate lesion histology (for 
example discriminating inflammatory from fibrotic strictures in Crohn disease) or 
explore the molecular profile of cancer. Moreover, PET/MR  provides superior soft 
tissue contrast to noise ratio and signal to noise ratio,which are fundamental in 
evaluating soft tissue pathology commonly encounted in abdominopelvic and breast 
imaging (1,12,20). MR is also capable of providing functional information, like 
diffusion weighted imaging (DWI) and the resultant apparent diffusion coefficient 
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(ADC) that may further enhance PET performance. Meanwhile, PET can improve 
the specificity of DWI and of ADC values.  
The synergism of PET/MR, and the possibility to obtain unique hybrid functional 
metabolic biomarkers, that could potentially provide insights into tissue composition 
and molecular features of lesions, inspired us to investigate PET/MR in oncology 
and in Crohn’s disease (CD).   
 
Role of [18F]-FDG PET/CT in Crohn’s disease 
 
Several groups have evaluated the use of PET in Crohn disease (CD). Skehan et 
al. in 25 paediatric patients with suspected IBD, 15 of whom with CD, found that 
[18F]-FDG PET had an overall sensitivity of 81% and a specificity of 85%. Moreover, 
when colonoscopy was limited, PET localized further inflammatory areas in the 
proximal large bowel. Authors concluded that PET is a useful technique in children 
and it may be used an adjunct to colonoscopy and barium studies when they are 
unsuccessful (21).  
Several years later, the same group confirmed that PET identified active 
inflammatory disease in 81.5% of CD patients, according to endoscopic results. 
Therefore, although PET cannot replace conventional studies, it might be 
considered as an alternative technology in the appropriate clinical setting, keeping 
in mind the associated radiation exposure (22). Also, Loffler et al. performed FDG-
PET in 23 paediatric patients, 17 of whom with CD, obtaining a sensitivity and 
specificity equal to 98% and 68% with histology as standard of reference, and 92% 
and 65% with endoscopy as standard of reference, respectively (23). They 
considered PET as a fast, non-invasive imaging method with low radiation exposure 
that allows the assessment of disease activity in children at an early stage.   
Other authors evaluated the accuracy of FDG-PET to non-invasively assess 
inflammation in 43 CD patients, using ileocolonoscopy and magnetic resonance 
enterography (entero-MR) as reference standards. PET results were comparable 
to entero-MR for the assessment of the proximal ileum, and complementary to 
colonoscopy to assess the nature of strictures, suggesting PET as a promising non-
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invasive technique for clinical management of CD (24). The same group compared 
PET to entero-MR and anti-granulocyte scintigraphy (GAB) in 59 patients with 
active CD. PET had the highest sensitivity (85%) followed by entero-MR (67%) and 
GAB (41%), while it demonstrated lower specificity (89%) than entero-MR (93%) 
and GAB (100%). Authors concluded that non-invasive detection of inflamed gut 
segments in CD with PET offers high sensitivity and specificity (25).  
Berthold et al. (26) compared PET versus PET/CT in 23 children and adolescents, 
19 of whom with CD, using endoscopy with biopsy and histology as gold standard. 
The authors demonstrated that, although CT provided additional anatomical 
information, only PET was able to locate the active disease in the gut segments. 
Moreover, PET detected extra intestinal inflammation, and allowed the assessment 
of the extent and degree of high-grade inflammation, especially in those small bowel 
segments that were not accessible to endoscopy. Several authors have 
investigated whether CT provides better anatomical details, improving the 
diagnostic accuracy of PET, for the assessment of inflammation in adult and 
paediatric patients with CD. Bettenworth et al. (27) performed PET/CT in 25 patients 
with histologically diagnosed Crohn’s colitis. PET/CT was positive in 88% of 
extensive ulcerations, but only in 50% of superficial epithelial lesions. The author 
concluded that PET/CT is a non-invasive and promising translational method. 
Moreover, they found that the intestinal glucose uptake is variable and pathologic 
segments might be difficult to distinguish from normal ones.  The same group 
compared [18F]-FDG PET/CT, entero-MR and trans-abdominal ultrasound in order 
to evaluate the best non-invasive imaging method for the detection and 
differentiation of inflammatory and fibromatous stenoses in CD, using endoscopy 
and histology as reference standards. A combination of trans-abdominal ultrasound 
and PET/CT or entero-MR led to a 100% detection rate (28). Jacene et al. (29) 
preoperatively investigated the accuracy of PET/CT in CD patient with obstructive 
symptoms in comparison to postoperative histopathological analyses of these 
lesions. In their study, different lesions demonstrated FDG uptake, including 
inflammatory lesions, fibrotic strictures and muscle hypertrophy. The authors 
suggested that, although a qualitative PET analysis is sensitive, a semi-quantitative 
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analysis could help identifying patients with active inflammation, using the 
maximum lean standardized uptake value (SULmax). Another group studied the 
clinical utility of PET/CT in 7 patients, 4 of whom with CD, and showed that PET/CT 
can be viewed as a useful imaging method in diagnosis, management and clinical 
decision-making of patients with known or suspected CD (30). Louis and colleagues 
in a prospective study, which included 22 patients with active CD, found that 
PET/CT detected 35 of 48 endoscopically affected segments, with a sensitivity and 
a specificity of 72.9% and 55.3%, respectively. Furthermore, severe endoscopic 
lesions, such as deep ulcers and strictures, were detected by PET/CT with a 
sensitivity of 100%, suggesting a direct correlation between PET sensitivity and 
clinical significativity. Overall, PET/CT scores correlated with clinical parameters, 
endoscopy and biological activity of CD (31). Meisner et al. conducted another study 
using PET/CT for the assessment of disease activity in 12 patients with IBD, 7 of 
whom with CD. In their study, PET/CT was positive in 59.4% of segments and there 
was 81.3% correlation between PET activity and clinical activity, demonstrating 
utility of PET as a non-invasive technique to identify active inflammatory regions in 
CD (32).  The feasibility and potential clinical utility of [18F]-FDG PET/CT for the 
assessment of CD activity was also investigated in a study performed by Saboury 
et al. in which 22 subjects underwent PET/CT followed by ileocolonoscopy in order 
to correlate imaging results with clinical and endoscopic findings. PET/CT detected 
15 additional segments compared to those visualized by endoscopy and all global 
PET parameters correlated with standard clinical scores (CDAI), allowing a new 
quantitative analysis of regional and global CD activity using PET imaging (33). 
Recently, Russo and colleagues evaluated the role of [18F]-FDG PET/CT as a 
marker of progression of inflammatory activity and its response to anti-TNF therapy 
in 22 patients with CD. PET/CT sensitivity and specificity were respectively 88% 
and 70%; moreover, SUV correlated with clinicopathological markers like C-reactive 
protein and Harvey-Bradshaw Index (34).  
Other authors studied the CD activity combining [18F]-FDG PET with CT 
enteroclysis or CT enterography. Das et al. included in a prospective study 17 
patients, 9 of whom with CD, using PET/CT enteroclysis in order to obtain both 
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morphological and functional details. PET/CT enteroclysis outperformed barium 
studies and colonoscopy in detecting affected segments in the small and large 
bowel (50 versus 16 versus 17 segments respectively). Furthermore, PET/CT 
enteroclysis detected also extra-intestinal abnormalities and differentiated active 
from fibrostenotic CD (35). Ahmadi and colleagues examined the role of combined 
[18F]-FDG PET/CT enterography (CTe) in active CD. CTe identified 48 abnormal 
small bowel segments as well as PET. The authors also found a correlation 
between CTe score and SUVmax, suggesting a similar sensitivity of both imaging 
methods; moreover, PET provided additional information quantifying the degree of 
inflammation in abnormal small bowel segments (36).  
Groshar et al. performed [18F]-FDG PET/CTe in 28 patients with known or 
suspected CD in order to correlate the CTe score and SUVmax for the assessment 
of the grade and severity of inflammation in abnormal segments. They detected 85 
abnormal segments in 22 patients, with a good correlation between SUVmax and 
CTe measurements of mural thickness and enhancement, concluding that SUVmax 
might be a reliable parameter to quantify CD activity (37).  
Finally, Shyn et al. compared [18F]-FDG PET/CTe with CTe alone with the purpose 
of evaluating the diagnostic efficacy of the two imaging methods in 13 patients with 
CD. Different parameters such as CTe severity score, SUVmax, simplified 
endoscopic score, and clinical parameters correlated with pathology inflammation 
grade. In 3 patients, PET detected active inflammation and an enterocolonic fistula, 
not revealed by CTe alone. SUVmax strongly correlated with disease activity, 
suggesting that PET/CTe might improve the detection and grading of active 




PET/MR in IBD: advantages and disadvantages 
 
Hybrid PET/MR scanners are the most advanced, clinically approved devices 
available for in-vivo diagnostic imaging. They can simultaneously (co-acquisition) 
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or sequentially acquire metabolic data from positron emission tomography (PET) 
as well as functional and morphologic information from magnetic resonance (MR) 
(1,2).  
In the setting of co-acquisition, the PET and MR components of this hybrid 
technology simultaneously image the same body region, allowing a nearly complete 
spatial and temporal matching of PET and MR data. This spatial and temporal 
matching is not achievable by sequential PET/MR scanners neither by PET/CT, 
with the latter being limited by the necessarily asyncronous acquisition of the PET 
events and the CT data (1). The matching of the PET and MR data translates into 
the possibility of exploring a queried lesion, for example a thickened bowel loop, 
with a large array of PET and functional MR (fMR) biomarkers that include, among 
others, SUVmax, metabolic volume (MV), apparent diffusion coefficient (ADC), and 
volume transfer coefficient (Ktrans). This would be precluded, due to bowel 
peristalsis and patient movements, in the case of sequentially acquired PET and 
MR scans.  
Secondarily PET/MR co-acquisition may symbiotically overcome some limitations 
of each modality taken apart (6). Moreover, serially acquired high temporal 
resolution MR data can track and quantitate patient and bowel motion allowing for 
MR-assisted PET motion correction with subsequent reduction in PET related 
motion artifacts, noise, blurring, and increased contrast (6,7).   
Another important advantage of PET/MR compared to PET/CT is the reduced 
radiation burden to the patient.  PET/MR allows a 20% reduction in radiation 
exposure compared to PET/CT, when the CT component is used for attenuation 
correction only, or up to 60-73%  if the CT part is employed both for attenuation 
correction and for producing diagnostic quality CT images (39,40).  
The geometry of the PET components of the PET/MR scanners, with the resultant 
increased sensitivity in the center of the PET field of view (FOV), allows reducing 
activity to up to 30-50% of that required for comparable quality PET from PET/CT 
(41).   
Moreover, the lengthier times required to acquire MR sequences might be used to 
prolong PET acquisition, improving the quality of the PET images and/or allowing a 
	 15	
lower activity. In a phantom study, increasing bed position time by a factor of 8, from 
2 minutes to 16 minutes, allowed reducing to 1/8 (12.5%) the injected activity, with 
PET images displaying same signal to contrast ratio as those obtained from 100% 
activity while using 2 minutes per bed position (42).  
This is extremely important in CD patients who are usually younger at presentation 
and will likely require several follow-up studies in the course of their disease. 
A major disadvantage of PET/MR compared to PET/CT relies in its limits in 
quantifying the attenuation exerted by body tissues on the gamma-rays. While in 
PET/CT the density of the tissues, as measured by CT Hounsfield units, may be 
used to compute the linear attenuation correction (LAC), this is not the case of 
PET/MR where the signal intensity of the tissue does not have any direct relations 
with the LAC. Several techniques have been employed to address this issue, the 
most effective being tissue segmentation/decomposition and atlas based methods. 
However, this problem has not been resolved completely. But new approaches 
based on artificial intelligence seem very promising. 
Another potential disadvantage of PET/MR, compared to PET/CT, is the lengthier 
acquisition time (23-30 minutes for a Crohn’s PET/MR protocol versus 12-15 
minutes for a Crohn’s PET/CT study), with MR acquisition being the time limiting 
factor. However,  neither PET nor MR quality should be compromised if intention is 
to maximize clinical benefit from PET/MR capabilities.  
Most of the research efforts in clinical PET/MR have been deployed in neurologic 
and oncologic imaging.  In selected indications, PET/MR has been proven 
advantageous over PET/CT, and also over PET and MR performed separately. For 
example,  PET/MR improves staging of central nervous system cancers, detection 
of satellite brain lesions, residual disease, and evaluation of intratumoral 
heterogeneity (43–47). 
In oncologic body imaging PET/MR has been demonstrated to be superior to 
PET/CT and also to MR in several respects, including evaluation of liver, peritoneal, 
bone, and lymph node metastases, and whole-body staging of different primary 
cancers. Moreover, PET/MR can also provide insights into the tumor biology, as in 
the case of breast cancer (48–57). 
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PET/MR has enormous potentialities also in the evaluation of Crohn’s disease. 
However, it has been rarely used in this disease, with only two research 
manuscripts available in the literature (25,31,58-60).  
PET/MR might increase the diagnostic confidence in assessing patients affected by 
Crohn’s disease. It has been shown that MR enterography, PET/CT enterography, 
and PET/MR enterography had similar accuracy in detecting areas affected by 
Crohn’s disease. However PET/MR enterography provided additional clinically 
relevant information due to its increased accuracy in assessing extra-luminal 
manifestations of the disease, that were associated with higher need for stoma [p = 
0.022], and also distant localization [p = 0.002] (59). 
PET/MR enterography was also useful in assessing the dominant nature of 
strictures. Strictures constitute one of the most important clinical challenges in 
Crohn’s disease. They occur in about 11% of patients at presentation, and their 
prevalence increases over time. Moreover, they represent a major cause of 
morbidity in Crohn’s disease (28,61,62). 
While several medical options are available for predominantly inflammatory 
strictures, the fibrotic ones need to be treated more invasively, by surgery or 
mechanical dilatation. This pivotal information, however, is not usually available to 
the clinicians, due to the limits of current techniques, even in the case of endoscopic 
biopsy. Therefore patients are usually treated conservatively first, and in the case 
of failure, a surgical approach is pursued (28,61,62). 
In two very recent PET/MR studies focused on this very specific topic, with surgical 
pathology as standard of reference, it was found that PET/MR could be useful to 
differentiate between fibrotic and inflammatory strictures. 
PET/MR enterography was more accurate in detecting fibrosis compared with 
PET/CT enterography [p = 0.043] and with MR enterography [p = 0.024] (59). 
Among the different PET/MR biomarkers that were investigated, the best 
discriminator between fibrosis and active inflammation was the hybrid PET/MR 
enterography biomarker ADC*SUVmax, that at a cutoff of less than 3000, was 
associated with accuracy, sensitivity, and specificity of 71%, 67%, and 73%, 
respectively for purely fibrotic strictures (60). 
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PET/MR in neoplastic patients: advantages and disadvantages 
 
PET/MR has several potential advantages over PET/CT and over MR and PET 
standing alone in oncologic imaging. The simultaneous acquisition of PET and MR 
data allows for complete spatial and temporal matching of MR and PET data and 
makes it possible to compensate for motion both MR and PET data. This translates 
into the possibility to improve image quality, increase detection rate, provide more 
precise quantitative assessment of lesion pharmacokinetics and metabolism (1,58). 
Moreover, the high signal to noise and contrast to noise ratios of MR, and the 
resultant high quality anatomic layout, allow to better localize areas of abnormal 
metabolism detected by PET, especially in critical areas, like the subcapsular liver 
parenchyma and the pelvis, and to pin point lesions that, because of small size or 
critical location or high background activity or low intrinsic metabolism, might be 
missed by PET alone (58). This can be advantageous in improving clinical staging 
and restaging, ascertaining the benign or malignant nature of lesions, providing an 
anatomic-metabolic road map to the surgeons, and investigate the biology of 
cancers (57,58).  
PET and MR together may play a pivotal role in several oncologic entities, 
complementing each other. One of this field might be neuro-oncology. Contrast 
enhanced MR, by itself, is the method of choice for the initial evaluation and follow 
up of brain tumors. However, contrast enhancement of lesions is imperfect being 
influenced by several factors related to tumor biology, e.g. blood flow and vessel 
permeability, and to brain physiology, e.g., the blood-brain barrier. Therefore, 
reduction of lesion enhancement after therapy does not always correlate with tumor 
response.  Although PET can rely on specific tracers exploring selective features of 
tumor biology, like amino acid transport (11C-methionine and 18F-
fluoroethyltyrosine), hypoxia (18F-fluoromisonidazole), and proliferation (18F-
fluoroethylthymidine), it is influenced by blood perfusion to the affected areas and 
by local permeability. For example, MR can help PET to discriminate the transport 
and metabolic trapping of 18F-fluoroethylthymidine allowing a better quantification 
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of tumor cell proliferation. It is expected that PET/MR can overcome the limitations 
of each technique when used separately (6). PET/MR may prove useful for a more 
accurate pre-surgical planning showing the relationships of the metabolic vital 
portions of brain tumors with adjacent white matter tracts, infiltration and 
displacement. Moreover, it is capable of highlighting functionally important areas 
that need to be spared such as Broca's area. It has already been demonstrated that 
PET/MR can change the radiation target volume when compared to stand alone 
MR or PET (63).  
In the field of body oncology, PET/CT represents the gold standard technique for 
the staging of several solid organ neoplasms and it has been shown to allow a more 
accurate TNM staging than CT or PET alone (8,9). PET can detect metabolically 
active lesions and quantify the amount of radiotracer uptake, expressed as standard 
uptake value (SUV), with several cut off values proposed to discriminate malignant 
from benign lesions. Quantification of radiotracer uptake has also been shown 
helpful in assessing treatment response by following changes in lesion metabolism 
(10,11). Despite its attributes, PET/CT has limitations imposed by the low intrinsic 
soft tissue contrast of CT, and by physiologic radiotracer uptake in normal tissues 
that may render lesions with a low metabolic rate (e.g, well-differentiated 
hepatocellular carcinoma, mucinous adenocarcinomas, neuroendocrine tumors, 
and some low-grade lymphomas) difficult to detect. Neoplastic lesions in or 
adjacent to tissues with normally high metabolism (e.g., liver, kidneys) may be 
overlooked (12–19). 
PET/MR couples the advantages of PET with the superior soft tissue contrast of 
MR allowing for the improved assessment of fine anatomical detail, and the clear 
depiction of lesion margins, local tumor infiltration, and the relationship of lesions to 
adjacent structures. One such application can be in evaluating extention of rectal 
cancers beyond the tunica muscularis and threatening of the mesorectal fascia that 
might be very hard to assess by PET/CT, unless extensive (1,12,20). Moreover, 
MR is also capable of providing functional information with diffusion weighted 
imaging (DWI), perfusion imaging, and spectroscopy which may be used for lesion 
detection and characterization.  
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DWI is particularly valuable in the assessment of lesion cellularity, and may be used 
as a whole-body screening technique for the detection of hyper-cellular neoplasms, 
including lesions less than 10mm in diameter (64,65). DWI greatly contributes to 
the sensitivity of PET/MR. In our experience it is equivalent to PET in identifying 
neoplastic metabolically active lesions and is superior to PET in identifying 
neoplastic lesions with low metabolic activity. While highly sensitive, DWI suffers 
from low specificity. Lesions detected at DWI may be better characterized with a 
combination of morpho-functional MR criteria and metabolic PET criteria leading to 
increased specificity and improved readers’ confidence. These include similarity of 
signal intensity of the lesion with that of the primary neoplasm, areas of internal 
necrosis as on T2 weighted and on contrast enhanced images, apparent diffusion 
coefficient (ADC) values <1.4x10-3mm/s for distant metastases and <1.0x10-3mm/s 
for lymphadenopathy (66–68), SUV≥ 2.5 (10,11); satisfaction of these criteria allows 
to call a  lesion as malignant (10,11,66–69). In our experience, the superior ability 
of PET/MR to characterize subcentimeter lesions as benign or malignant allows for 
increased staging accuracy over other modalities.  
PET/CT may detect small foci of radionuclide uptake due to the PET component. 
However, due to the low soft tissue contrast of CT and the sequential nature of data 
acquisition inherent to PET/CT, lesion localization may suffer in some 
circumstances, and anatomic correlates for small PET findings may be overlooked. 
Conversely, concurrent data acquisition with PET/MR allows each modality to help 
the other in an additive manner. PET/MR will often help detecting small lesions that 
may be ignored by either modality alone.  Specific instances include small 
peritoneal lesions that may be missed by MR or miss-interpreted by FDG-PET as 
non-specific intestinal uptake (e.g., small foci of carcinomatosis in the 
supramesocolic region) (70–72). In our experience, PET/MR is particularly helpful 
in evaluating lymph node, liver, bone, pelvic organ, and breast. 
Size criteria are often used to differentiate benign from malignant lymph nodes on 
both MR and CT, with a short axis diameter of ≥ 10mm being a common threshold 
for malignancy (73). However, this method suffers from both low sensitivity and 
specificity as non-neoplastic conditions may result in “pathologic” lymph node 
	 20	
enlargement and small lymph nodes may harbor metastatic disease. In the setting 
of rectal cancer, up to 15% of pelvic lymph nodes less than 5mm are metastatic 
(69,74). MR-based morpho-functional indices, including lymph node T2-weighted 
characteristics, internal structure, shape, margin, and ADC value (ADC <1.0x10-
3mm/s suggesting malignancy), combined with metabolic PET data account for 
good performance figures of PET/MR in the assessment of lymph nodes below the 
10mm threshold. 
PET/MR is an ideal technique for oncologic liver imaging. MR alone, given its 
exquisite soft tissue resolution, is superior to CT alone in evaluating the liver 
parenchyma. PET improves the assessment of critical regions adjacent to the liver 
capsule and intrahepatic vasculature. Moreover PET facilitates the evaluation of 
areas that have undergone local regional therapies (e.g. TACE, thermal ablation, 
and SIRT) (75–77). Moreover, PET/MR value is not hampered by coexisting hepatic 
steatosis, a common limitation of CT in the setting of chemotherapy.  
Sclerotic bone metastases are readily detected by CT, however, subtle lytic 
metastases, particularly those lacking cortical breakthrough, are often overlooked. 
The sensitivity of CT for the detection of bone metastases is further reduced in 
patients with osteopenia.  FDG-PET will often identify pathologic FDG uptake in 
bone prior to the development of an anatomic CT correlate. PET/CT evaluation of 
bone is often confounded in the setting of increased hematopoietic bone marrow 
uptake from chemotherapy or colony stimulating factor administration, and is not 
sensitive in the detection of hypometabolic metastases (78–80). Specific 
radiotracers, such as 18F-Fluoride, may be used to improve PET detection of bony 
metastases (81,82).  PET/MR with FDG may identify subtle signal alterations on 
MR that provide anatomic correlates for otherwise indeterminate foci of FDG avidity, 
improving confidence in the diagnosis of bone metastases. STIR and DWI are 
sensitive for bone marrow edema; T1weighted imaging, including pre and post 
contrast imaging, is sensitive for sclerotic metastases as well as marrow replacing. 
In a comparative study it has been shown that whole body MR outperforms bone 
scintigraphy and targeted x-rays, being more sensitive for bone metastases from 
prostate cancer (sensitivity of 98-100% versus 86% respectively). However whole 
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body MR had similar specificity (specificity of 98-100% versus 98% 
respectively)(83). 
PET/MR has the potential to greatly improve the care of patients with pelvic 
cancers, a rather common entity.  For most pelvic cancers, accurate local staging 
is important for treatment planning. PET/CT imaging is limited in local staging due 
to the low soft tissue contrast and the presence of excreted radiotracer in the 
bladder that limits assessment of adjacent structures (84). MR alone is also limited, 
given the potentiality for metastatic disease in lymph nodes <10mm. PET/MR 
combines the improved T staging inherent to MR with the improved N staging of 
PET (85,86).   Furthermore, the low sensitivity of MR for the detection of small 
peritoneal implants and recurrent/residual disease after treatment may be improved 
in the presence of concurrent PET data (84–87). From our initial clinical and 
research activities, we feel that PET/MR will prove superior to MR or PET alone in 
both initial staging of pelvic cancers and post treatment surveillance. 
In our experience, PET/MR is extremely useful for breast cancer staging and follow 
up. The coaquisition of contrast enhanced MR and PET improves characterization 
of subcentimeter foci of non-mass like enhancement and improves the sensitivity 
for the detection of synchronous lesions.   
Several factors have the potential to hamper PET/MR performance. These are often 
related to the MR component of PET/MR. They include issues with lesion 
localization due to motion artifact (particularly in the region of the diaphragm, heart 
and bowel), and issues with image degradation due to magnetic susceptibility 
artifacts. PET/MR requires appropriate patient cooperation and is longer than 
PET/CT (average length 50-80 minutes according to the protocols). For patients 
unable to perform breath holds or hold still, PET/CT is preferred.   
Compared to CT, MR has lower temporal and spatial resolution, making PET/MR 
challenging in the setting of lung nodules less than 6mm in diameter.  However, 
Stolzman et al. (88), using a trimodality scanner to evaluate lung nodules on CT, 
MR, and PET, both separately and in various combinations, found similar detection 
rates for lung nodules on PET/MR (83%) and PET/CT (85%). These results are in 
keeping with a comparative study of PET/MR and PET/CT which showed that 
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PET/MR did not miss clinically relevant lung nodules in 134 consecutive oncologic 
patients (55).  
According to our preliminary clinical experience, PET/MR is not inferior to PET/CT 
in lung assessment and outperforms PET/CT in the detection and characterization 
of lymph nodes, bone metastases, and liver metastases, and in the staging of pelvic 
malignancies. Moreover, PET/MR can evaluate tumor regions such as the kidneys 
that are difficult to assess by PET/CT. PET/MT can also detect additional coexistent 
incidental neoplasms in the kidneys and breasts, not identified on PET/CT.  
Finally PET/MR suffers of the same contraindications as per MR only, including 
claustrophobia, metallic foreign bodies, ferromagnetic implants and devices. 
Moreover, because it is a relatively novel technology, there are no consolidated 
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